logo-loader
Sareum Holdings PLC

Sareum Holdings created drug to be showcased at leading cancer event next month

Sareum's partner Sierra Oncology has provided the essence of what it will share with delegates at the upcoming American Society of Clinical Oncology in Chicago

woman at microscope
Promising progress has been made, though the drug is at the early clinical phase

The findings from clinical trials of a cancer drug developed by Sareum Holdings PLC (LON:SAR) will be showcased at a leading international cancer conference next month.

SRA737 is one of a new breed of drugs called cell cycle checkpoint inhibitors. It is currently being developed by a Canadian firm called Sierra Oncology, which has carried out phase I/II trials on people with advanced forms of the disease.

An abstract from the data which is being shared at the American Society of Clinical Oncology (ASCO) in Chicago reveals the maximum dose for SRA737 used on its own as a monotherapy was 1,000mg a day, while the recommended phase II dose is 800mg.

It also said the phase II study will treat patients who are most likely genetically to benefit from checkpoint-1 inhibitors.

Well tolerated 

A second abstract reveals SRA737 is “well tolerated” when used in combination with chemotherapy. The first-in-human study also provided proof-of-concept that the chemo “effectively potentiates” (increases the power of) SRA737.

“This novel replication stress-targeted therapy warrants further evaluation in genetically pre-defined solid tumours,” the abstract adds.

Sierra Oncology chief executive, Dr Nick Glover, said: "The two studies have enrolled patients across a range of tumour indications including a variety of prospectively selected genetic contexts, allowing us to broadly survey the cancer landscape for activity signals in response to administration of SRA737 alone and in combination with non-cytotoxic low dose gemcitabine.

“These preliminary data have also enabled us to correlate clinical findings with tumour origin and genetic signature, ascertain whether the exogenous induction of replication stress via low dose gemcitabine can enhance SRA737's activity, and determine potential next steps in the development path for SRA737."

The ASCO event runs from May 31 to June 4. The information will go on display via a poster on June 1. For more details click here.

Separately, Sierra Oncology will be hosting an analyst and investor event from 6:00-7:00am on June 3 in Chicago to discuss these clinical findings and “potential next steps in the development strategy for SRA737”.

Sareum shares rose 8.5% to 0.7p.

 --- Adds share price ---

Quick facts: Sareum Holdings PLC

Price: £0.00

Market: AIM
Market Cap: £9.98 m
Follow

Watch

Sareum's Tim Mitchell upbeat after 'very successful' early-stage cancer trial

Sareum Holdings PLC (LON:SAR) chief executive Tim Mitchell caught up with Proactive London's Andrew Scott to discuss some preliminary efficacy data released on a drug that Sareum helped to develop. Of particular note was the impact SRA737 had in combination with a common chemotherapy...

on 3/6/19

2 min read

;